07:00 , May 5, 2016 |  BC Innovations  |  Targets & Mechanisms

Better call Delilah

Long non-coding RNAs (lncRNAs), once confined to the pile of non-functional genomic "junk," are now recognized to play key roles in gene regulation, and are increasingly being explored in various cancers. A Belgian group has...
07:00 , Mar 26, 2015 |  BC Innovations  |  Product R&D

Raising the CohBar

A recently discovered mitochondrial peptide with metabolic effects on skeletal muscle suggests mitochondrial DNA may deserve a second look as a source of therapeutic targets. A group from CohBar Inc. and the University of Southern...
07:00 , Mar 11, 2013 |  BC Week In Review  |  Company News

CohBar Inc., Alzheimer's Drug Discovery Foundation neurology news

CohBar received $205,260 in funding from ADDF to develop CohBar's Humanin analog, a mitochondrial peptide to treat Alzheimer's disease. ADDF's funding will support a year-long research program, including in vivo testing of the compound for...
07:00 , May 23, 2005 |  BC Week In Review  |  Company News

Neurologix, Keio University deal

NRGX received exclusive worldwide rights to use the university's humanin gene to develop and commercialize therapeutics to treat brain and other CNS disorders. The deal excludes the territory of Japan and the indication of amyotrophic...
07:00 , May 29, 2001 |  BioCentury  |  Tools & Techniques

Approaching late onset Alzheimer's

Two newly reported approaches to Alzheimer's disease appear to directly target the underlying mechanism of the disease. The two new targets, neprilysin and humanin, are likely to be complementary to the secretase inhibitors currently in...
07:00 , May 29, 2001 |  BC Week In Review  |  Company News

Keio University School of Medicine other research news

University researchers and colleagues published in the Proceedings of the National Academy of Sciences that a 24 residue peptide, humanin, protects neural cells from cell death caused by mutants of genes associated with familial AD...